|
|
 Previous Article | Table of Contents | Next Article 
In Vivo Effects of Flt3/Flk2 Ligand on Mobilization of Hematopoietic Progenitors in Primates and Potent Synergistic Enhancement With Granulocyte Colony-Stimulating Factor
Thalia Papayannopoulou,
Betty Nakamoto,
Robert G. Andrews,
Stewart D. Lyman, and
Minako Y. Lee
From the Division of Hematology, the Department of Biological Structure, and the Department of Pediatrics Hematology/Oncology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; and Immunex Corp, Seattle, WA.
The Flt3 receptor is expressed in primitive hematopoietic cells and its ligand exerts proliferative effects on these cells in vitro in synergy with other cytokines. To expand on the functional properties of Flt3 ligand (FL) in vivo we treated nonhuman primates with FL and tested its ability to mobilize stem/progenitor cells when given alone or in combination with granulocyte colony-stimulating factor (G-CSF ) treatment. FL alone (200 µg/kg/day) mobilizes progenitors with slow kinetics and with a peak effect at the end of 2 weeks of treatment. The spectrum of mobilized progenitors includes myeloid, lymphoid, megakaryocytic, and osteoclastogenic but a low proportion of burst-forming unit (BFU)e. Bone marrow (BM) studies before and during the treatment suggested that proliferative effects in BM may have preceded effects on peripheral blood mobilization. To assess the synergy of FL with G-CSF in mobilization of progenitors we used two schemes: one in which G-CSF was used for the last 5 days of a 12-day treatment with FL; the other in which both cytokines were given concurrently for 5 days only (FL, 200 µg/kg; G-CSF, 100 µg/kg). Both schemes yielded much higher progenitor mobilization levels (peak levels of colony-forming cells [CFSs] 41,000 to 95,000/mL blood) than observed with either FL (CFC 4,600 to 7,300/mL) or G-CSF (8,405 ± 3,024/mL) used alone at the same doses. Furthermore, there was a progressive and significant expansion of progenitors in vitro during 2 weeks in suspension cultures of mononuclear cells or of CD34+ cells only in the animal with the combined treatment. Likewise, substantial mobilization of osteoclastogenic progenitors was documented only with the combined treatment. Given the functional properties of FL, its synergistic mobilization with G-CSF, and its anticipated good tolerance (because of the absence of an effect on mast cell activation), a clinical use is projected for this cytokine in peripheral blood transplantation settings, as well as in experiments with ex vivo gene transfer.
Blood, Vol. 90 No. 2 (July 15), 1997:
pp. 620-629
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Papayannopoulou and D. T. Scadden
Stem-cell ecology and stem cells in motion
Blood,
April 15, 2008;
111(8):
3923 - 3930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ulyanova, L. M. Scott, G. V. Priestley, Y. Jiang, B. Nakamoto, P. A. Koni, and T. Papayannopoulou
VCAM-1 expression in adult hematopoietic and nonhematopoietic cells is controlled by tissue-inductive signals and reflects their developmental origin
Blood,
July 1, 2005;
106(1):
86 - 94.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Hematti, S. E. Sellers, B. A. Agricola, M. E. Metzger, R. E. Donahue, and C. E. Dunbar
Retroviral transduction efficiency of G-CSF+SCF-mobilized peripheral blood CD34+ cells is superior to G-CSF or G-CSF+Flt3-L-mobilized cells in nonhuman primates
Blood,
March 15, 2003;
101(6):
2199 - 2205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Siegel, D. Yeldell, D. M. Goldenberg, M. G. Stabin, R. B. Sparks, R. M. Sharkey, A. Brenner, and R. D. Blumenthal
Red Marrow Radiation Dose Adjustment Using Plasma FLT3-L Cytokine Levels: Improved Correlations Between Hematologic Toxicity and Bone Marrow Dose for Radioimmunotherapy Patients
J. Nucl. Med.,
January 1, 2003;
44(1):
67 - 76.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Lean, K. Fuller, and T. J. Chambers
FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function
Blood,
November 1, 2001;
98(9):
2707 - 2713.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. King, D. Horowitz, S. B. Dillon, R. Levin, A. M. Farese, T. J. MacVittie, and L. M. Pelus
Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GRO{beta}
Blood,
March 15, 2001;
97(6):
1534 - 1542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rosenzweig, T.J. MacVittie, D. Harper, D. Hempel, R.L. Glickman, R.P. Johnson, A.M. Farese, N. Whiting-Theobald, G.F. Linton, G. Yamasaki, et al.
Efficient and Durable Gene Marking of Hematopoietic Progenitor Cells in Nonhuman Primates After Nonablative Conditioning
Blood,
October 1, 1999;
94(7):
2271 - 2286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. PAPAYANNOPOULOU
Hematopoietic Stem/Progenitor Cell Mobilization: A Continuing Quest for Etiologic Mechanisms
Ann. N.Y. Acad. Sci.,
April 30, 1999;
872(1):
187 - 199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Schilz, G. Brouns, O. G. Ottmann, D. Hoelzer, A. A. Fauser, A. J. Thrasher, and M. Grez
High Efficiency Gene Transfer to Human Hematopoietic SCID-Repopulating Cells Under Serum-Free Conditions
Blood,
November 1, 1998;
92(9):
3163 - 3171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gratwohl, L. John, H. Baldomero, J. Roth, A. Tichelli, C. Nissen, S.D. Lyman, and A. Wodnar-Filipowicz
FLT-3 Ligand Provides Hematopoietic Protection From Total Body Irradiation in Rabbits
Blood,
August 1, 1998;
92(3):
765 - 769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Craddock, B. Nakamoto, R. G. Andrews, G. V. Priestley, and T. Papayannopoulou
Antibodies to VLA4 Integrin Mobilize Long-Term Repopulating Cells and Augment Cytokine-Induced Mobilization in Primates and Mice
Blood,
December 15, 1997;
90(12):
4779 - 4788.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
